Akari Therapeutics Receives New Round

  • Feed Type
  • Date
    9/22/2015
  • Company Name
    Akari Therapeutics
  • Mailing Address
    Undisclosed New York, NY 11101 USA
  • Company Description
    Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    Undisclosed
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Akari plans to use the anticipated net proceeds from the private placement for the clinical development of Coversin.
  • M&A Terms
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    Undisclosed